X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.fiercepharma.com/pharma/astrazeneca-finally-drops-roxadustat-us-rights-after-fda-rejection-trial-failure
https://www.globenewswire.com//news-release/2024/02/26/2835490/33525/en/FibroGen-Regains-All-Rights-to-Roxadustat-from-AstraZeneca-in-the-United-States-and-Other-AstraZeneca-Territories-Except-China-and-South-Korea.html
https://www.globenewswire.com//news-release/2023/12/09/2793446/33525/en/FibroGen-Presents-Data-from-Phase-3-MATTERHORN-Trial-of-Roxadustat-in-Patients-with-Anemia-of-Lower-Risk-Transfusion-Dependent-Myelodysplastic-Syndromes-at-American-Society-of-Hema.html
https://www.fiercebiotech.com/biotech/fibrogen-faces-more-trouble-clinic-dmd-drug-fails-phase-3-trial
https://www.fiercepharma.com/pharma/fibrogen-azs-evrenzo-finally-chalks-win-chemo-induced-anemia-china
https://www.globenewswire.com/news-release/2023/05/18/2671783/33525/en/FibroGen-Announces-Positive-Topline-Results-from-China-Pivotal-Phase-3-Clinical-Trial-of-Roxadustat-for-the-Treatment-of-Chemotherapy-Induced-Anemia.html
https://www.globenewswire.com/news-release/2023/05/05/2662452/33525/en/FibroGen-Announces-Results-for-MATTERHORN-a-Phase-3-Clinical-Study-of-Roxadustat-for-the-Treatment-of-Anemia-in-Patients-with-Myelodysplastic-Syndromes-MDS.html
https://www.fiercepharma.com/pharma/astellas-writes-340m-fibrogens-evrenzo-joins-gsk-nixing-cell-therapy-collab-adaptimmune
https://endpts.com/adcomm-offers-mixed-vote-recommends-gsks-kidney-disease-drug-in-just-one-patient-population/
https://www.fiercebiotech.com/research/hypoxia-boosts-fetal-hemoglobin-red-blood-cells
https://www.globenewswire.com/news-release/2022/08/26/2505234/33525/en/FibroGen-Announces-Completion-of-Patient-Enrollment-in-MATTERHORN-a-Phase-3-Clinical-Study-of-Roxadustat-for-the-Treatment-of-Anemia-in-Patients-with-Lower-Risk-Transfusion-Depende.html
https://www.prnewswire.com/news-releases/european-nephrologists-lead-the-way-with-adoption-of-astellasfibrogens-hif-ph-inhibitor-evrenzo-roxadustat-for-anemia-of-ckd-treatment-in-both-dialysis-and-non-dialysis-settings-spherix-report-finds-301577399.html
https://www.fiercepharma.com/marketing/spurned-fda-fibrogen-and-astellas-find-anemia-drug-evrenzo-support-nice
https://www.fiercepharma.com/pharma/astellas-fibrogens-roxadustat-pads-safety-case-pooled-analysis
https://www.fiercepharma.com/pharma/astrazeneca-fibrogen-disagree-roxadustats-us-path-chronic-kidney-disease-anemia
https://endpts.com/fibrogen-ceo-roxa-path-blocked-as-astrazeneca-remains-undecided-on-just-what-it-plans-to-do-in-the-wake-of-a-crl/
https://www.prnewswire.com/news-releases/spherix-uncovers-key-differences-in-the-management-of-chronic-kidney-disease-patients-in-europe-versus-the-us-301530834.html
https://www.fiercepharma.com/pharma/fibrogens-roxadustat-safety-data-draws-sec-attention-astrazeneca-partnered-anemia-drug-stays
https://www.fiercepharma.com/marketing/astrazeneca-fibrogen-keep-roxadustat-s-anemia-dream-alive-new-fda-meeting
https://www.biopharmadive.com/news/fibrogen-layoffs-roxadustat-fda-meeting/609825/
https://www.fiercebiotech.com/biotech/gsk-pulls-off-clean-sweep-endpoint-hits-anemia-phase-3-positioning-it-to-leapfrog
https://www.fiercepharma.com/pharma/glaxosmithkline-s-novel-anemia-drug-succeeds-where-astrazeneca-fibrogen-akebia-failed
https://www.globenewswire.com/news-release/2021/10/25/2319699/33525/en/FibroGen-Announces-Analyses-from-Roxadustat-Global-Phase-3-Program-at-American-Society-of-Nephrology-Kidney-Week-2021.html
https://www.fiercepharma.com/pharma/fibrogen-astellas-roxadustat-wins-blessing-eu-but-anemia-drug-s-fate-remains-limbo-stateside
https://www.globenewswire.com/news-release/2021/08/19/2283933/33525/en/Astellas-Receives-European-Commission-Approval-for-First-in-Class-EVRENZO-roxadustat-for-Adult-Patients-with-Symptomatic-Anemia-of-Chronic-Kidney-Disease.html
https://www.fiercepharma.com/pharma/as-roxadustat-lost-fda-s-favor-akebia-ceo-touts-first-class-opening-for-its-anemia-contender
https://www.fiercepharma.com/pharma/fibrogen-s-longtime-cfo-hands-baton-to-j-j-veteran-as-high-profile-roxadustat-blowup-cues
https://www.globenewswire.com/news-release/2021/08/11/2278626/33525/en/FibroGen-Receives-Complete-Response-Letter-from-the-FDA-for-Roxadustat-for-Anemia-of-Chronic-Kidney-Disease.html
https://endpts.com/safety-concerns-push-fda-adcomm-to-vote-overwhelmingly-against-approval-for-fibrogen-anemia-drug/
https://www.fiercepharma.com/pharma/fibrogen-admits-to-messing-safety-data-for-anemia-drug-roxadustat-as-analysts-dramatically
https://www.fiercepharma.com/pharma/fibrogen-admits-to-messing-safety-data-for-anemia-drug-roxadustat-as-analysts-dramatically
https://endpts.com/fibrogen-shares-take-a-beating-as-ceo-reveals-a-switch-up-in-the-safety-data-presented-for-anemia-drug/
https://www.biopharmadive.com/news/fibrogen-shares-sink-as-fda-meeting-decision-suggests-another-delay-for-top/595953/
https://icer.org/news-insights/press-releases/icer-publishes-evidence-report-on-roxadustat-for-treating-anemia-in-chronic-kidney-disease/
https://www.fiercepharma.com/pharma/az-fibrogen-s-roxadustat-decision-delayed-by-fda-but-approval-still-likely-analysts
https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-us-regulatory-review-of-roxadustat-in-anaemia-of-chronic-kidney-disease.html
https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-us-regulatory-review-of-roxadustat-in-anaemia-of-chronic-kidney-disease.html
https://www.globenewswire.com/fr/news-release/2020/12/02/2138189/0/en/FibroGen-to-Present-Safety-and-Efficacy-Analyses-from-Roxadustat-Global-Phase-3-Program-at-American-Society-of-Hematology-Annual-Meeting.html
http://www.pharmafile.com/news/564829/japan-approves-astellas-and-fibrogens-evrenzo-chronic-kidney-disease-patients-currently-
https://www.prnewswire.com/news-releases/astellas-receives-approval-of-evrenzo-roxadustat-in-japan-for-the-treatment-of-anemia-of-chronic-kidney-disease-in-adult-patients-not-on-dialysis-301181047.html
https://www.prnewswire.com/news-releases/astellas-receives-approval-of-evrenzo-roxadustat-in-japan-for-the-treatment-of-anemia-of-chronic-kidney-disease-in-adult-patients-not-on-dialysis-301181047.html
https://endpts.com/fibrogens-new-phiii-data-set-it-up-for-quick-ok-analysts-say-but-can-it-avoid-a-black-box-warning/?utm_medium=email&utm_campaign=1089%20-%20GSK%20pays%20angry%20discovery%20partner%20to%20protect%20its%20oncology%20strategy%20Stelios%20Papadopoulos%20jumps%20into%20the%20SPAC%20game%20Basic&utm_content=1089%20-%20GSK%20pays%20angry%20discovery%20partner%20to%20protect%20its%20oncology%20strategy%20Stelios%20Papadopoulos%20jumps%20into%20the%20SPAC%20game%20Basic+CID_842d26f8e652b473f76b5d6c176e8621&utm_source=ENDPOINTS%20emails&utm_term=FibroGens%20new%20PhIII%20data%20set%20it%20up%20for%20quick%20OK%20analysts%20say%20But%20can%20it%20avoid%20a%20black%20box%20warning
https://www.prnewswire.com/news-releases/new-roxadustat-data-in-anemia-of-chronic-kidney-disease-to-be-released-at-asn-kidney-week-2020-reimagined-301154302.html
https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-advances-leadership-in-renal-disease-with-more-than-80-abstracts-at-asn-kidney-week-2020-reimagined.html
https://www.biospectrumasia.com/news/96/16954/astellas-to-present-new-roxadustat-data-in-anemia-of-ckd-at-asn-kidney-week-.html
https://www.globenewswire.com/news-release/2020/06/08/2045228/0/en/FibroGen-Announces-New-Roxadustat-Data-Presented-at-2020-ERA-EDTA-Virtual-Congress.html
https://www.prnewswire.com/news-releases/roxadustat-demonstrates-non-inferiority-to-darbepoetin-in-phase-3-dolomites-study-of-anemia-in-non-dialysis-dependent-adult-patients-with-chronic-kidney-disease-301071723.html
https://www.prnewswire.com/news-releases/european-medicines-agency-accepts-astellas-marketing-authorization-application-for-roxadustat-301063148.html
Market Place
Share 
